Report
Valens Research

XRAY - Embedded Expectations Analysis - 2021 06 29

DENTSPLY SIRONA, Inc. (XRAY:USA) currently trades near corporate averages relative to UAFRS-based (Uniform) earnings, with a 24.5x Uniform P/E. At these levels, the market is pricing in bullish expectations for the firm, but management may have concerns about their growth rates, product launches, and the Axeos imaging business

Specifically, management may have concerns about their chairside business growth outlook, regional promotions for Axeos, and the success of their demand creation tools. Also, they may lack confidence in their ability to sustain revenue growth, control SG&A spending, and meet cost savings targets. In addition, they may be overstating the potential of their digital dentistry assets, the potential of their implants and endodontics product launches, and the capabilities of their Axeos imaging unit
Underlying
DENTSPLY SIRONA Inc.

DENTSPLY SIRONA is a manufacturer of dental products and technologies. The company's Consumables segment is responsible for the design, manufacture, sales and distribution of the company's dental consumable products which include preventive, restorative, endodontic, and dental laboratory products. The company's Technologies and Equipment segment includes responsibility for the design, manufacture, sales and distribution of the company's dental technology and equipment products and healthcare consumable products, including dental implants, computer-aided design/computer-aided manufacturing systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, and consumable medical device products.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch